BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that Mary Rozenman, Ph.D., Senior Vice President of Corporate Development and Strategy at Aimmune, will present a company overview at Cantor Fitzgerald’s 2nd Annual Healthcare Conference in New York City, on Tuesday, July 12, 2016, at 3:30 p.m. Eastern Time.
